Ulisse Biomed S.p.A. Share Price

Equities

UBM

IT0005451213

Biotechnology & Medical Research

Real-time Borsa Italiana 08:43:41 29/04/2024 BST 5-day change 1st Jan Change
1.28 EUR -2.66% Intraday chart for Ulisse Biomed S.p.A. +5.28% -21.75%

Financials

Sales 2023 * 341K 365K 29.19M Sales 2024 * 1.42M 1.52M 122M Capitalization 28.36M 30.4M 2.43B
Net income 2023 * -1M -1.07M -85.59M Net income 2024 * - 0 0 EV / Sales 2023 * 76.8 x
Net cash position 2023 * 2.19M 2.35M 188M Net cash position 2024 * 2.36M 2.53M 202M EV / Sales 2024 * 18.3 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 9
Yield 2023 *
-
Yield 2024 *
-
Free-Float 92.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.52%
1 week+5.28%
Current month-10.69%
1 month-9.12%
3 months-21.99%
6 months-16.18%
Current year-21.75%
More quotes
1 week
1.19
Extreme 1.185
1.34
1 month
1.19
Extreme 1.185
1.43
Current year
1.19
Extreme 1.185
1.90
1 year
1.19
Extreme 1.185
2.52
3 years
0.97
Extreme 0.97
7.55
5 years
0.97
Extreme 0.97
7.55
10 years
0.97
Extreme 0.97
7.55
More quotes
Managers TitleAgeSince
Founder 39 -
Founder - -
Chief Executive Officer 41 -
Members of the board TitleAgeSince
Director/Board Member 60 -
Chief Executive Officer 41 -
Director/Board Member 56 -
More insiders
Date Price Change Volume
29/04/24 1.28 -2.66% 13 000
26/04/24 1.315 +7.79% 28,000
25/04/24 1.22 -3.94% 4,000
24/04/24 1.27 -0.39% 26,000
23/04/24 1.275 +3.66% 5,000

Real-time Borsa Italiana, April 29, 2024 at 08:43 am

More quotes
Ulisse Biomed Spa is an Italy-based company engaged in the healthcare biotech sector. The Company focuses on creating new and transformative diagntostic platforms and products. It creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Chiffre d''affaires - Rate of surprise